Comparative Pharmacology
Head-to-head clinical analysis: REVERSOL versus RIVASTIGMINE TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REVERSOL versus RIVASTIGMINE TARTRATE.
REVERSOL vs RIVASTIGMINE TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversal agent for neuromuscular blockade; inhibits acetylcholinesterase, increasing acetylcholine concentration at nicotinic receptors to reverse nondepolarizing neuromuscular blocking agents.
Reversible, non-competitive inhibitor of acetylcholinesterase and butyrylcholinesterase, increasing acetylcholine concentration in the CNS.
0.25-0.5 mg/kg IV bolus over 10 seconds, repeated if necessary up to a maximum total dose of 2 mg/kg.
Initial 1.5 mg orally twice daily; increase by 1.5 mg twice daily at ≥2-week intervals to maximum 6 mg twice daily if tolerated.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in healthy adults (mean 10 hours). In hepatic impairment, increases up to 18 hours; in severe renal impairment (CrCl <30 mL/min), half-life may extend to 24 hours.
The terminal elimination half-life is approximately 1.5 hours after oral administration. However, due to slow dissociation from the cholinesterase enzyme, the pharmacodynamic half-life (duration of enzyme inhibition) is about 10 hours, supporting twice-daily dosing.
Primarily renal excretion of unchanged drug (60-70%). Fecal elimination accounts for 20-25% via biliary secretion. Minor metabolism (<10%) with metabolites also renally cleared.
Rivastigmine is extensively metabolized by cholinesterase-mediated hydrolysis to the inactive decarbamylated metabolite, NAP226-90, which is then excreted renally. Approximately 97% of a dose is excreted in urine as metabolites (<1% as parent drug), and about 0.4% in feces. Renal elimination accounts for >90% of total clearance.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor